We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+12.57%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$750M
AUM Growth
+$262M
Cap. Flow
+$205M
Cap. Flow %
27.3%
Top 10 Hldgs %
28.71%
Holding
137
New
15
Increased
36
Reduced
40
Closed
5

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$14.3M
2
ALGN icon
Align Technology
ALGN
+$13.8M
3
WBA
Walgreens Boots Alliance
WBA
+$13.5M
4
AMGN icon
Amgen
AMGN
+$12M
5
CNC icon
Centene
CNC
+$9.49M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$4.67M
2
SYK icon
Stryker
SYK
+$4.15M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$1.91M
4
BDX icon
Becton Dickinson
BDX
+$1.79M
5
ZBH icon
Zimmer Biomet
ZBH
+$1.75M

Sector Composition

Rank Sector Weight
1 Healthcare 92.09%
2 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
51
Cigna
CI
$74.5B
$4.83M 0.64%
33,000
-4,722
-13% -$696K
CERN
52
DELISTED
Cerner Corp
CERN
$4.38M 0.58%
74,500
-24,000
-24% -$1.3M
NKTR icon
53
Nektar Therapeutics
NKTR
$2.31B
$4.04M 0.54%
11,467
-933
-8% -$210K
GNMK
54
DELISTED
GenMark Diagnostics, Inc
GNMK
$4.01M 0.53%
+312,666
New +$3.76M
COO icon
55
Cooper Companies
COO
$14B
$4M 0.53%
80,000
– –
JNJ icon
56
Johnson & Johnson
JNJ
$609B
$3.92M 0.52%
31,500
-6,500
-17% -$776K
HUM icon
57
Humana
HUM
$48B
$3.92M 0.52%
19,000
+3,500
+23% +$724K
CHRS icon
58
Coherus Oncology
CHRS
$216M
$3.7M 0.49%
175,000
– –
MCK icon
59
McKesson
MCK
$98.5B
$3.56M 0.47%
24,000
– –
IBB icon
60
iShares Biotechnology ETF
IBB
$9.23B
$3.52M 0.47%
36,000
+24,000
+200% +$2.3M
HALO icon
61
Halozyme
HALO
$9.23B
$3.5M 0.47%
270,000
-48,000
-15% -$607K
ESRX
62
DELISTED
Express Scripts Holding Company
ESRX
$3.26M 0.43%
49,500
– –
LIVN icon
63
LivaNova
LIVN
$4.43B
$3.15M 0.42%
+64,189
New +$3.12M
DXCM icon
64
DexCom
DXCM
$29.6B
$3.06M 0.41%
144,400
-19,600
-12% -$383K
NBIX icon
65
Neurocrine Biosciences
NBIX
$17.2B
$2.94M 0.39%
68,000
-7,000
-9% -$300K
RARE icon
66
Ultragenyx Pharmaceutical
RARE
$2.88B
$2.85M 0.38%
42,000
-1,000
-2% -$76.2K
XRAY icon
67
Dentsply Sirona
XRAY
$2.81B
$2.81M 0.37%
+45,000
New +$2.71M
BLUE
68
DELISTED
bluebird bio
BLUE
$2.64M 0.35%
2,239
– –
AGIO icon
69
Agios Pharmaceuticals
AGIO
$2.36B
$2.63M 0.35%
45,000
– –
CVS icon
70
CVS Health
CVS
$137B
$2.62M 0.35%
33,400
+23,700
+244% +$1.89M
TSRO
71
DELISTED
TESARO, Inc.
TSRO
$2.46M 0.33%
+16,000
New +$2.6M
SGEN
72
DELISTED
Seagen Inc. Common Stock
SGEN
$2.45M 0.33%
39,000
-4,000
-9% -$250K
NUVA
73
DELISTED
NuVasive, Inc.
NUVA
$2.34M 0.31%
31,304
-3,696
-11% -$268K
ALKS icon
74
Alkermes
ALKS
$8.79B
$2.31M 0.31%
39,500
-3,000
-7% -$170K
QGENF
75
DELISTED
QIAGEN NV
QGENF
$2.3M 0.31%
79,444
-12,056
-13% -$349K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2017 Portfolio in Review

As of Q1 2017, Bellevue Group held 137 positions worth $750M, up 54% from $488M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $205M of net new capital in Q1 2017, opening 15 new positions and adding to 36 existing holdings. Its largest new stake was Align Technology: 136,200 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Stryker, an estimated $4.15M trimmed.

  • Bellevue Group's largest Q1 2017 buy was Align Technology: 136,200 shares worth $15.6M.
  • Bellevue Group added most to Elevance Health in Q1 2017, an estimated $14.3M increase.
  • Bellevue Group's biggest Q1 2017 reduction was Stryker, cutting an estimated $4.15M.
  • Bellevue Group fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $4.67M.
  • Bellevue Group's ten largest holdings make up 29% of its $750M portfolio in Q1 2017.
  • Bellevue Group opened 15 new positions and closed 5 in Q1 2017.
  • Bellevue Group's portfolio value rose 54% quarter-over-quarter to $750M.

Based on Bellevue Group's 13F filing for Q1 2017, filed 11 May 2017.